Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery Font : A-A+
WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation. Radiopharmaceutical therapy is a promising approach to treat cancer and other diseases using radioactive metals bound with proteins/antibodies to target and kill cells. Actinium-225 (Ac-225) is emerging as a radioactive isotope of choice for radiopharmaceuticals due to favorable properties such as its long half-life, high potency, and induction of localized cell death.